Title: Neuroprotective effect of the different dosage of recombinant human erythropoietin on neonatal hypoxia ischemia encephalopathy
Abstract: Objective: To evaluate the neuroprotective effect and safety of the different dosage of recombinant human erythropoietin(rhEPO) on neonatal hypoxia-ischemia encephalopathy(HIE).Methods: 76 cases HIE suited to the including criteria were randomized to either low dose EPO-treated group(29 cases) with the dosage of 300 U/kg/time,or high dose EPO-treated group(23 cases) with the dosage of 500 U/kg/time or control group(24 cases) without EPO treatment.rhEPO was injected subcutaneous for the first time and then instead of intravenous for each other day with 3 times each week for a duration of2 weeks.The supportive care was same among the groups.Neurological scoring was evaluated at postnatal day(PND) 3,5 and 7.Neonatal behavioral neurological assessment(NBNA) was evaluated at postnatal day 7,14 and 28.Blood pressure,liver and renal function,blood electrolytes and blood hemoglobin,platelet and reticular red blood cell count were monitored before and after treatment in all the infants.Results: ①The scoring of NBNA showed a significant difference between EPO treated groups and control group.There was no significant difference between two EPO groups.②The significant difference of the neurological scoring was achieved at seventh day of birth,which was significant lower in EPO treated group compared with control group.③There were no difference in the liver and renal function,blood electrolytes,blood pressure and platelet count among three groups after treatment,except the hemoglobin and reticular red blood cell count increased in the rhEPO treated group.Conclusion: 300 U/kg or 500 U/kg dosage of rhEPO treatment on neonatal HIE infants could promote neurological recovery with the same effect.There was no serious side effect with rhEPO treatment.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot